Ascentage Pharma Group International (AAPG) Current Deferred Tax Assets (2023 - 2025)

Ascentage Pharma Group International (AAPG) has reported Current Deferred Tax Assets for 3 consecutive years, with $183.4 million the latest figure, recorded in Q4 2025.

• Quarterly Current Deferred Tax Assets rose 328.35% year-over-year to $183.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $183.4 million (up 328.35% YoY) and the FY2025 annual result came in at $186.0 million, up 341.48% from the prior year.
• Current Deferred Tax Assets climbed to $183.4 million in Q4 2025 per AAPG's latest filing, from $93.4 million in the prior quarter.
• Over the last five years, Current Deferred Tax Assets for AAPG reached as high as $183.4 million in Q4 2025 and fell as low as $42.8 million in Q4 2024.
• A 3-year average of $94.2 million and a median of $75.2 million in 2025 frame the typical range for Current Deferred Tax Assets.
• Annual changes were most pronounced in 2024 — Current Deferred Tax Assets dropped 24.81% — and 2025, when it soared 328.35%.
• Year by year, Current Deferred Tax Assets stood at $56.9 million in 2023, then retreated by 24.81% to $42.8 million in 2024, then surged by 328.35% to $183.4 million in 2025.
• According to Business Quant data, Current Deferred Tax Assets over the past three periods registered $183.4 million, $93.4 million, and $42.8 million for Q4 2025, Q2 2025, and Q4 2024 respectively.